- Home
- BMEA vs CATO Comparison
BMEA vs CATO Comparison
Compare BMEA & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- CATO
- Stock Information
- Founded
- BMEA 2017
- CATO 1946
- Country
- BMEA United States
- CATO United States
- Employees
- BMEA N/A
- CATO N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- CATO Clothing/Shoe/Accessory Stores
- Sector
- BMEA Health Care
- CATO Consumer Discretionary
- Exchange
- BMEA Nasdaq
- CATO Nasdaq
- Market Cap
- BMEA 65.8M
- CATO 55.7M
- IPO Year
- BMEA 2021
- CATO N/A
- Fundamental
- Price
- BMEA $1.44
- CATO $2.56
- Analyst Decision
- BMEA Strong Buy
- CATO
- Analyst Count
- BMEA 11
- CATO 0
- Target Price
- BMEA $27.60
- CATO N/A
- AVG Volume (30 Days)
- BMEA 703.1K
- CATO 43.9K
- Earning Date
- BMEA 05-05-2025
- CATO 05-22-2025
- Dividend Yield
- BMEA N/A
- CATO 13.28%
- EPS Growth
- BMEA N/A
- CATO N/A
- EPS
- BMEA N/A
- CATO N/A
- Revenue
- BMEA N/A
- CATO $642,949,000.00
- Revenue This Year
- BMEA N/A
- CATO N/A
- Revenue Next Year
- BMEA N/A
- CATO N/A
- P/E Ratio
- BMEA N/A
- CATO N/A
- Revenue Growth
- BMEA N/A
- CATO N/A
- 52 Week Low
- BMEA $1.29
- CATO $2.19
- 52 Week High
- BMEA $13.07
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- BMEA 39.69
- CATO 47.88
- Support Level
- BMEA $1.29
- CATO $2.50
- Resistance Level
- BMEA $1.52
- CATO $2.89
- Average True Range (ATR)
- BMEA 0.14
- CATO 0.19
- MACD
- BMEA 0.01
- CATO 0.01
- Stochastic Oscillator
- BMEA 28.17
- CATO 28.85
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.